Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis

This study suggests that omalizumab might be an interesting therapeutic strategy in ABPA, associated with less side effects compared to long-term corticosteroids. Further randomized-controlled trials are needed to ascertain the efficacy of omalizumab in CF patients with ABPA.